Connor Clark & Lunn Investment Management Ltd. Invests $495,000 in The Chemours Company $CC

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in The Chemours Company (NYSE:CC) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 43,207 shares of the specialty chemicals company’s stock, valued at approximately $495,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Chemours by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company’s stock worth $223,069,000 after buying an additional 1,263,047 shares during the period. Millennium Management LLC boosted its stake in Chemours by 60.4% during the 1st quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company’s stock worth $54,428,000 after acquiring an additional 1,515,520 shares during the last quarter. American Century Companies Inc. grew its holdings in Chemours by 17.5% during the first quarter. American Century Companies Inc. now owns 1,909,149 shares of the specialty chemicals company’s stock valued at $25,831,000 after purchasing an additional 284,130 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Chemours by 10.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,438,732 shares of the specialty chemicals company’s stock valued at $19,466,000 after purchasing an additional 136,460 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Chemours by 8.8% in the second quarter. Bank of New York Mellon Corp now owns 1,054,620 shares of the specialty chemicals company’s stock worth $12,075,000 after purchasing an additional 85,529 shares during the period. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Stock Down 2.0%

NYSE:CC opened at $10.72 on Thursday. The stock has a 50-day simple moving average of $14.27 and a 200 day simple moving average of $13.21. The Chemours Company has a 52-week low of $9.13 and a 52-week high of $22.38. The company has a market cap of $1.61 billion, a PE ratio of -4.83 and a beta of 1.64. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71.

Chemours (NYSE:CC) last released its quarterly earnings results on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.04). The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.50 billion. Chemours had a positive return on equity of 35.27% and a negative net margin of 5.70%.The company’s revenue was down .9% compared to the same quarter last year. During the same period last year, the company earned $0.40 EPS. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Friday, November 14th will be paid a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, November 14th. Chemours’s dividend payout ratio is -15.77%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Truist Financial decreased their price target on shares of Chemours from $21.00 to $18.00 and set a “buy” rating for the company in a report on Monday, November 10th. Mizuho decreased their target price on Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Thursday, October 16th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a research report on Wednesday, October 8th. Royal Bank Of Canada decreased their price objective on Chemours from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Monday, November 10th. Finally, Zacks Research cut Chemours from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $17.50.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.